Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for young hemophilia patients: jivi safety trial shows promise for fewer injections

NCT ID NCT05147662

Completed Disease control Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study tested the safety of Jivi (BAY 94-9027), a longer-lasting clotting factor, in 36 children aged 7 to 12 with severe hemophilia A. The medicine is already approved for older patients, but this trial focused on younger kids to check for allergic reactions and whether the drug stops working well. Participants received injections twice a week for 6 months, then could switch to a schedule with up to 5 days between doses, and were monitored for 2 years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHILDREN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hemophilia A hemorrhagic disease severe hemophilia A

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHILDREN HEMOPHILIA A PROPHYLAXIS OF BLEEDING TREATMENT OF BLEEDING

Contacts and locations

Locations

  • Acibadem Adana Hastanesi, Çocuk Sagligi ve Hastaliklari, Çocuk Hematoloji-Onkoloji Bölümü

    Adana, 01130, Turkey (Türkiye)

  • Akdeniz Üniversitesi Tip Fakültesi Çocuk Sagligi ve Hastaliklari Anabilim Dali Çocuk Hematoloji ve Onkoloji Bilim Dali

    Antalya, 07059, Turkey (Türkiye)

  • Alberta Children's Hospital | Hematology / Oncology / Blood and Marrow Transplant Clinic

    Calgary, Alberta, T3B 6A8, Canada

  • Arnold Palmer Hospital for Children

    Orlando, Florida, 32806, United States

  • Ege Üniversitesi Tip Fakültesi, Çocuk Sagligi ve Hastaliklari Anabilim Dali, Çocuk Hematoloji Bilim Dali

    Izmir, 35100, Turkey (Türkiye)

  • Gaziantep Üniversitesi Tip Fakültesi, Sahinbey Arastirma Ve Uygulama Hastanesi, Çocuk Hematoloji ve Onkoloji Bilim Dali

    Gaziantep, 27100, Turkey (Türkiye)

  • HEMORIO

    Rio de Janeiro, Rio de Janeiro, 20211-030, Brazil

  • Hacettepe Üniversitesi Tip Fakültesi, Hacettepe Ihsan Dogramaci Çocuk Hastanesi,

    Ankara, 06230, Turkey (Türkiye)

  • Hosp Clínicas Facult. Med. de Ribeirão Preto / USP

    Ribeirão Preto, São Paulo, 14051-140, Brazil

  • Hospital das Clínicas de Campinas - UNICAMP

    Uberlândia, Minas Gerais, 13083-878, Brazil

  • Hospital de Niños Sor María Ludovica

    La Plata, Buenos Aires, 1900, Argentina

  • Instituo Hematología Arbesú

    Godoy Cruz, Mendoza Province, 5501, Argentina

  • Instituto de Hematología Dr. Rubén Dávoli

    Rosario, Santa Fe Province, S2000CKF, Argentina

  • Irmandadade da Santa Casa de Misericordia de Sao Paulo (iSANTACASA)

    São Paulo, São Paulo, 01223-001, Brazil

  • McMaster University Medical Centre | McMaster Children's Hospital | Hematology

    Hamilton, Ontario, L8N 3Z5, Canada

  • OUS Rikshospitalet Klinisk Forskningspost Barn

    Oslo, Oslo, 0372, Norway

  • Ondokuz Mayis Üniversitesi Tip Fakültesi, Saglik Uygulama ve Arastirma Merkezi, Çocuk Sagligi ve Hastaliklari Anabilim Dali

    Samsun, 55200, Turkey (Türkiye)

  • Ospedale Pediatrico Bambino Gesù - Oncoematologia, Trapianto Emopoietico e Terapie Cellulari

    Roma (RM), Lazio, 00165, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.